Stocks · Healthcare · Biotechnology
Crescent Biopharma, Inc. CBIO
$14.32 +0.42% Close, Oct 2, 2026 · NASDAQ · Market cap $531.9M
Expensive vs sectorHigh risk
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 691.6% in a year.
- The stock is 47% below its highest close of the past year.
- The company holds net cash of $170.2M (cash above total debt).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth, 3-year CAGRTop 2%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 10%
- Gross marginTop 2%
- Operating marginBottom 10%
- Accruals (lower is better)Top 4%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 14%
- Free-cash-flow yieldBottom 17%
- EBITDA / enterprise valueBottom 14%
- Sales / enterprise valueBottom 16%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 31%
- 6-month returnBottom 19%
- 1-year return vs S&P 500Top 43%
- Distance from 52-week highBottom 31%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 20%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 30%
- Upside to consensus price targetTop 33%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 20%
- Maximum drawdown, 3 yearsBottom 3%
- Beta vs S&P 500 (lower is better)Top 44%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Gross margin | 100.0% | — | Top 2% | |
| Operating margin | -1417.7% | — | Bottom 10% | |
| Net margin | -1371.5% | — | — | |
| Free-cash-flow margin | -1292.8% | — | — | |
| Return on invested capital | -102.3% | — | Bottom 10% | |
| Revenue growth, 3-year CAGR | 424.9% | — | Top 2% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -49.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 124.6%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -33.44%
- Shareholder yield
- -33.44%
- Share count change, 1 year
- +691.6%
- Share count change, 3-year CAGR
- +262.2%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 30, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- -22.3%
- Average 2-day reaction, last 8
- -0.8%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $31.25
- Target vs current price
- +118.2%
- Analysts with a rating
- 14
- Share rating Buy or Strong Buy
- 64%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 30, 2026 | -0.6% | +1.7% | +6.8% | +22.0% | — |
| Apr 29, 2026 | +17.6% | -12.6% | -24.5% | -13.2% | -32.0% |
| Feb 26, 2026 | -80.6% | -1.1% | -8.0% | -5.7% | +62.0% |
| Nov 6, 2025 | -25.7% | +5.4% | +5.0% | +4.5% | -23.3% |
| Aug 6, 2025 | -83.3% | -5.2% | +11.9% | +14.1% | +7.8% |
| May 14, 2025 | +99.2% | -5.5% | +3.5% | -34.4% | -49.2% |
| Feb 13, 2025 | +31.3% | +9.2% | +16.1% | -0.1% | -7.5% |
| Nov 13, 2024 | -36.4% | +1.6% | -4.1% | -29.1% | -30.2% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | -$0.74 | -$0.74 | -0.6% | — |
| Apr 29, 2026 | -$0.70 | -$0.85 | +17.6% | $1.0M |
| Feb 26, 2026 | -$4.01 | -$2.22 | -80.6% | $10.8M |
| Nov 6, 2025 | -$1.27 | -$1.01 | -25.7% | — |
| Aug 6, 2025 | -$4.93 | -$2.69 | -83.3% | — |
| May 14, 2025 | -$0.04 | -$5.00 | +99.2% | — |
| Feb 13, 2025 | -$0.11 | -$0.16 | +31.3% | — |
| Nov 13, 2024 | -$0.15 | -$0.11 | -36.4% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 30.44× | — | — | Bottom 16% |
| Free-cash-flow yield | -28.88% | — | — | Bottom 17% |
| Earnings yield | -52.93% | — | — | Bottom 14% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- +0.6%
- 200-day average slope (20 days)
- +2.0%
- Distance from 50-day average
- -14.9%
- Distance from 200-day average
- -9.0%
- RSI (14)
- 35.6
- Relative volume
- 0.51×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 77.8%
- Volatility vs own 5-year history
- 40th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.01
- Correlation with S&P 500
- 0.13
- Current drawdown from 1-year high
- -46.9%
- Maximum drawdown, 3 years
- -97.4%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 23, 2020 | Feb 13, 2026 | -97.9% | 1290 days | Not yet recovered |
| Oct 12, 2020 | Nov 3, 2020 | -24.9% | 16 days | 6 days (Nov 11, 2020) |
| Nov 18, 2020 | Dec 9, 2020 | -13.2% | 14 days | 9 days (Dec 22, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $531.9M
- EPS, diluted (TTM)
- -$7.58
- Revenue (TTM)
- $11.9M
- 52-week range
- $8.72 – $27.41
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $1.2M | $75,000 | $10,000 | $0 | $10.8M |
| Gross profit | $1.2M | $75,000 | $10,000 | $0 | $10.8M |
| Operating income | -$63.4M | -$47.4M | -$39.3M | -$49.9M | -$152.6M |
| Net income | -$63.4M | -$46.7M | -$36.9M | -$48.5M | -$153.9M |
| EPS (diluted) | -$123.27 | -$88.88 | -$58.25 | -$63.22 | -$14.78 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $10.8M | $1.0M | $0 |
| Net income | -$9.8M | -$17.9M | -$15.1M | -$21.8M | -$24.6M | -$92.4M | -$23.3M | -$22.7M |
| EPS (diluted) | -$15.24 | -$27.71 | -$19.63 | -$5.65 | -$1.49 | -$4.58 | -$0.77 | -$0.74 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$57.5M | -$46.5M | -$34.9M | -$31.1M | -$71.5M |
| Capital expenditure | -$14,943 | -$84,191 | -$21,394 | -$9,972 | -$72.9M |
| Free cash flow | -$57.5M | -$46.5M | -$34.9M | -$31.1M | -$144.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $10.7M | $4.2M | $28.7M | $0 | $321.7M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $171.6M
- Total assets
- $182.8M
- Total liabilities
- $19.5M
- Total debt
- $1.4M
- Net debt
- -$170.2M
- Shareholders’ equity
- $163.3M
As of Jun 30, 2026 (filed Jul 30, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Jan 13, 2023 | $0.24 | — |
| Sep 21, 2022 | $1.43 | — |
Short interest
- Shares sold short
- 3,407,158
- Days to cover
- 8.51
- Change vs previous report
- +7.4%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jun 16, 2025
- 1-for-100